Celgene (CELG) Partner Acceleron Initiates ACE-536 Phase 2
- Dollar Tree (DLTR) to Acquire Family Dollar (FDO) for $74.50/Share
- Hospira (HSP) May Acquire Danone's Medical-Nutrition Business in $5B Deal - WSJ
- Carl Icahn Makes Quick $174M from Family Dollar Stores (FDO) Sale
- Virgin America Files for U.S. IPO
- Cummins, Inc. (CMI) Tops Q2 EPS by 5c; Boosts Revenue Growth Outlook
Acceleron Pharma, Inc., announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. Patients and healthcare providers currently have limited options for the treatment of beta-thalassemia. This is the second ongoing Phase 2 trial for ACE-536, which is being developed by Acceleron as part of a global collaboration with Celgene Corporation (Nasdaq: CELG).
You May Also Be Interested In
- Incyte (INCY) Jakafi Receives FDA Approval for Expanded Labeling
- Market Wrap: Housing Sales Miss in June; Earnings Abound; SodaStream 'Pops' on Speculation
- Advaxis (ADXS) Receives Patent Coverage in Japan for Lm-LLO Cancer Immunotherapy Platform Tech
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!